Sodium Channel Blocker Tolerance as a Metric for Disease Modification in Dravet Syndrome
Koichiro Yuji, Wakako Yuji · 2026
Read Sodium Channel Blocker Tolerance as a Metric for Disease Modification in Dravet Syndrome by Koichiro Yuji, Wakako Yuji (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13580336.txt.
Description
Koichiro Yuji and Wakako Yuji argue that a new gene therapy for Dravet syndrome should face its hardest test: living with drugs it once forbade, in a 2026 commentary. The therapy lifts output of a sodium channel that calming brain cells need, and early trials cut seizures. Sodium channel blockers are banned in this disease because they weaken those same calming cells and worsen seizures.
If the therapy truly restores the channel, the ban's reason should melt away. Trial plans still exclude patients on those drugs, leaving the question open by design. The authors point to emergency care, where one blocker is already allowed for runaway seizures, as a natural record to mine. Incidental exposures in follow up studies could show whether the old harm still strikes.
Catalog record
| CREATOR | Koichiro Yuji, Wakako Yuji |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 4310 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |